(1 - 30 von 50
)
Exelixis files IND for anti-cancer drug - UPI.com
www.upi.com
Exelixis said Friday it submitted an investigational new drug application to the Food and Drug Administration for its new cancer treatment.
Biogen Idec board extends contract of CEO George Scangos
www.boston.com
The board of Biogen Idec Inc. has extended the contract of its top executive with the same base salary, but the opportunity to earn more in incentive pay....
Biogen Idec ernennt George Scangos zum CEO
www.finanznachrichten.de
Exelixis-CEO und ehemaliger Vorsitzender der Biotechnologiesparte von Bayer bringt starke wissenschaftliche Kompetenz und weitreichende Erfahrung in der Biotech- und Pharmabranche
Spatenstich für die hochmoderne biopharmazeutische Produktionsanlage...
www.biogen-solothurn.ch
Unter ihnen waren der Schweizer Bundespräsident Johann Schneider-Ammann, Biogen Chief Executive Officer George Scangos, Biogen Executive Vice President John Cox, ...
Exelixis Announces George A. Scangos, Ph.D. to …
www.wallstreet-online.de
Exelixis, Inc. (Nasdaq: EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Scangos will ...
Aktienrückkauf geplant: Biogen-Chef Scangos legt …
www.finanzen.net
Konzernchef George Scangos (68) kündigte am Donnerstag bei der Vorlage der Quartalszahlen seinen Rücktritt an. Bereits in einigen Monaten solle es soweit sein, sobald ein Nachfolger gefunden sei.
FOCUS: Unternehmen: Biogen-Chef Scangos legt zum …
Beim Biotechkonzern Biogen stehen die Zeichen auf Veränderung: Konzernchef George Scangos (68) kündigte am Donnerstag bei der Vorlage der Quartalszahlen seinen Rücktritt an.
Biogen-Chef George Scangos: „Die Bedrohung hat zugenommen“
www.handelsblatt.com
George Scangos ist Chef von Biogen und Präsident des amerikanischen Pharmaverbandes. Im Interview spricht er über dünnen Margen bei ...
FDA approves Biogen drug for lead genetic cause of infant death |...
www.reuters.com
The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in...
Biogen Appoints Michel Vounatsos Executive Vice President, Chief...
www.finanznachrichten.de
Nachrichten » Biogen Appoints Michel Vounatsos Executive Vice ... Michel Vounatsos Executive Vice President, Chief Commercial ... to George Scangos, ...
George Scangos Biography - Harvard Business School
www.hbs.edu
George Scangos Biography George A. Scangos, Ph.D. was appointed Chief Executive Officer and a member of the Board of Directors of Biogen Idec in June He joined the company from Exelixis, Inc., where he served as President and CEO and a director since October From September to October 1996, Dr. Scangos served as
FOCUS: Unternehmen: Für Biogen Idec zahlt sich Kampf …
Für das laufende Jahr peilt Unternehmenschef George Scangos nun ein Ergebnis pro Aktie vor Sonderposten von 8,65 bis 8,85 US-Dollar an, wie Biogen am Montag mitteilte.
Investors see Biogen CEO choice as friendly to potential takeover |...
www.reuters.com
The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious...
Exclusive: Biogen shortens name, expands ambitions in Alzheimer's,...
www.reuters.com
Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has...
Biogen CEO George Scangos — SACC-NE
www.sacc-ne.org
Biogen CEO George Scangos · April 11, Christina Bjornstrom. It was exciting to see such a great turnout at our event with Biogen CEO George Scangos. We learned so much about where drug discovery is headed and Biogen's perspective on why and how drugs are priced the way they are.
UPDATE 3-Biogen names Exelixis' Scangos CEO | Reuters
www.reuters.com
Biogen names George Scangos new CEO. * Scangos previously CEO of Exelixis Inc. * Scangos takes over from retired Jim Mullen. * Biogen ...
Biogen Idec Inc. (NASDAQ:BIIB) - Biogen CEO George Scangos Will Be...
www.benzinga.com
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of ...
Biogen chief George Scangos to step down - STAT
www.statnews.com
Biogen chief George Scangos to step down. By Robert Weisman — Boston Globe. July 21, Twitter · Facebook · LinkedIn · Email · Doximity; Print. George ...
As Biogen CEO steps down, analysts see challenges ahead - The Boston...
www2.bostonglobe.com
The Cambridge biotech giant is financial sound but must address waning sales growth and limited near-term prospects for new blockbuster products.
People in the News: Jennifer Van Eyk, George Scangos | GenomeWeb
www.genomeweb.com
Jennifer Van Eyk has been named the inaugural director of Cedars-Sinai's Advanced Clinical Biosystems Research Institute, Cedars-Sinai said this week. She also...
George Scangos Archives - MedCity News
medcitynews.com
This stance on keeping drug pricing aloft helps Biogen CEO George Scangos rationalize the ever-increasing price of its multiple sclerosis drug Avonex. Share.
George Scangos - Latest News and breaking headlines - Benzinga
www.benzinga.com
Following an announcement by Biogen Inc (NASDAQ: BIIB) elevating Michel Vounatsos, the company's chief commercial officer and a recent ...
Fireside Chat with George Scangos, former CEO Biogen; CEO Vir...
calendar.ucsf.edu
George has been named one of the 25 most influential people in biotech, leading Biogen for six years before leaving at the end of Sales at Biogen more...
"Drug Discovery & Development, Current Status and Future Prospects" -...
www.babcne.org
We are a non-profit international business association built on professional and cultural relationships between the United States and the United Kingdom to...
Biogen CEO Quits Amid M&A Speculation; Company Hikes Outlook | Stock...
www.investors.com
Biogen chief George Scangos is leaving after six up-and-down years.
Biogen CEO: Crush drug prices, and you crush drug R&D - MedCity News
medcitynews.com
Biogen CEO George Scangos says that if you lower drug pricing, you risk having a weak pipeline for the future.
sortiert nach Relevanz / Datum